Valuation: Mendus AB

Market Cap 40Cr 4.16Cr 3.65Cr 3.37Cr 3.11Cr 5.9Cr 398.27Cr 6.02Cr 16Cr 194.9Cr 16Cr 15Cr 676.57Cr P/E 2026 *
-4.25x
P/E 2027 * -7.23x
Enterprise Value 8.36Cr 85.88L 75.33L 69.54L 64.26L 1.22Cr 82Cr 1.24Cr 3.25Cr 40Cr 3.23Cr 3.15Cr 139.69Cr EV / Sales 2026 *
9.34x
EV / Sales 2027 * 0.93x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.23%
1 week+15.79%
Current month+13.99%
1 month+31.74%
3 months+41.03%
6 months+12.24%
Current year+17.86%
1 week 5.63
Extreme 5.63
7.24
1 month 5
Extreme 5
7.49
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/22/28Buy

Chief Technology Officer

10,000 0.0050%
24/22/24Buy

Chief Financial Officer

20,000 0.0100%
24/22/24Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+15.79%-18.72%-35.80% 4.12Cr
-0.24%+1.85%+3.13%+8.40% 4.97TCr
-0.36%+1.21%+420.77%+597.43% 4.05TCr
-2.29%+3.83%+23.48%+56.80% 3.43TCr
-2.13%+0.29%+23.91%-7.13% 3.48TCr
-0.79%+2.02%+3.83%+36.42% 2.7TCr
+3.82%+3.51% - - 1.66TCr
-2.62%-2.13%+64.96%+120.02% 1.56TCr
-2.17%+6.65%+104.31%+102.15% 1.43TCr
-2.70%-2.04%+12.37%+17.77% 1.38TCr
Average -0.85%+4.82%+70.89%+99.56% 2.47TCr
Weighted average by Cap. -1.25%+4.37%+93.94%+134.21%

Financials

2026 *2027 *
Net sales 89.5L 9L 8L 7L 7L 13.04L 8.8Cr 13.3L 34.78L 4.31Cr 34.53L 33.77L 15Cr 22Cr 2.31Cr 2.02Cr 1.87Cr 1.73Cr 3.27Cr 220.82Cr 3.34Cr 8.72Cr 108.06Cr 8.66Cr 8.47Cr 375.13Cr
Net income -16Cr -1.67Cr -1.47Cr -1.36Cr -1.25Cr -2.37Cr -160.3Cr -2.42Cr -6.33Cr -78Cr -6.29Cr -6.15Cr -272.31Cr -1.86Cr -19.1L -16.75L -15.46L -14.29L -27.08L -18Cr -27.63L -72.23L -8.95Cr -71.71L -70.14L -31Cr
Net Debt -32Cr -3.3Cr -2.89Cr -2.67Cr -2.47Cr -4.68Cr -316.04Cr -4.77Cr -12Cr -154.66Cr -12Cr -12Cr -536.88Cr -20Cr -2.02Cr -1.78Cr -1.64Cr -1.51Cr -2.87Cr -193.78Cr -2.93Cr -7.65Cr -95Cr -7.6Cr -7.43Cr -329.19Cr
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
08/26/08 SEK 6.600 +1.54% 71,614
07/26/07 SEK 6.500 -4.27% 51,120
06/26/06 SEK 6.790 +11.13% 80,794
03/26/03 SEK 6.110 +2.52% 32,118
02/26/02 SEK 5.960 +4.56% 28,455
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.500SEK
Average target price
16.00SEK
Spread / Average Target
+146.15%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock